Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Molecular Cancer Therapeutics|February 15, 2018
In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial CancersGary Altwerger, Elena Bonazzoli, Stefania Bellone, et al.
Gynecologic Oncology|March 25, 2018
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinomaChanhee Han, Stefania Bellone, Eric R Siegel, et al.
Molecular Cancer Therapeutics|June 4, 2016
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu ExpressionJonathan Black, Gulden Menderes, Stefania Bellone, et al.
Molecular Cancer Therapeutics|December 14, 2016
Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer CellsEmiliano Cocco, Yang Deng, Erik M Shapiro, et al.
Gynecologic Oncology|November 30, 2016
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitroStefania Bellone, Eliana Bignotti, Silvia Lonardi, et al.
Cancer|December 7, 2021
A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instabilityStefania Bellone, Dana M Roque, Eric R Siegel, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 26, 2018
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitorsCharles Li, Elena Bonazzoli, Stefania Bellone, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 20, 2021
Integrated mutational landscape analysis of uterine leiomyosarcomasJungmin Choi, Aranzazu Manzano, Weilai Dong, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2019
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapyLuca Zammataro, Salvatore Lopez, Stefania Bellone, et al.
Pageof 8